Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide and VLCD for Muscle Preservation in Type 2 Diabetes
NCT05606471Phase 4Unknown
- Sponsor
- University of Nottingham
- Start
- Sep 2021
- Primary completion
- Jul 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), obesity, sponsored by University of Nottingham. Status: unknown.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05606471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05606471.